VivoSeq
Other

Moderate to Severe Glabellar Lines

3

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Moderate to Severe Glabellar Lines is an early-stage landscape with 3 programs across 8 companies. The most active players are AbbVie, Eli Lilly, Chongqing Claruvis Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1C

Chongqing Claruvis Pharmaceutical Co., Ltd.

2 programs

Phase 3R

Revance Therapeutics, Inc.

0 programs

PreclinicalDaewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

0 programs

PreclinicalE

EuBiologics Co.,Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

AGN-151586

AbbVie

Phase 22

YY003

Chongqing Claruvis Pharmaceutical Co., Ltd.

Vehicle Control

Lubris Bio Pty Ltd

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

35

clinical trials

Completed30 · 86%
Unknown status3 · 9%
Recruiting1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

35 trials

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
Recruiting·JJHM BioPharma (Tonghua) Co. , Ltd.·Phase 3·NCT06937944·669 enrolled
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
Not yet recruiting·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 3·NCT07013279·324 enrolled
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Completed·EEuBiologics Co.,Ltd·Phase 3·NCT04830345·290 enrolled
Treatment of Moderate to Severe Glabellar Lines
Completed·GGalderma R&D·Phase 3·NCT04249583·300 enrolled
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
Completed·GGalderma R&D·Phase 3·NCT05146999·132 enrolled
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
Completed·RRevance Therapeutics, Inc.·Phase 3·NCT03004248·2,691 enrolled
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
Completed·BBMI Korea·Phase 3·NCT05531968·278 enrolled
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
Completed·CChongqing Claruvis Pharmaceutical Co., Ltd.·Phase 3·NCT06499688·529 enrolled
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Completed·—·Phase 2·NCT05217355·50 enrolled
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Completed·—·Phase 3·NCT05321979·253 enrolled
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines
Completed·MMedy-Tox·Phase 3·NCT03216408·504 enrolled
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
Completed·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 1·NCT06212960·20 enrolled
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
Completed·AbbVie logoAbbVie·Phase 4·NCT00856414·45 enrolled
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Completed·Ipsen logoIpsen·Phase 3·NCT02353871·185 enrolled
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Completed·RRevance Therapeutics, Inc.·Phase 3·NCT03014622·303 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)